Name | Linifanib (ABT-869) | CAS# | 796967-16-3 | |
---|---|---|---|---|
Price | ¥Inquiry/1g | Purity | 98.9% | |
Stocking Period |
1 Day | Stock | In Stock |
Detail
Product Information
ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. |
Get all suppliers by the below link:
2024-07-15 |
Linifanib(ABT-869)
Price: Inquiry |
2020-01-06 |
Linifanib (ABT-869)
Price: $350.0 |
2018-05-10 |
ABT-869
Price: ¥2200.0 |
2017-06-12 |
Linifanib (ABT-869)
Price: ¥Inquiry |
2017-06-14 |
Linifanib (ABT-869)
Price: ¥Inquiry |
2017-11-14 |
ABT-869
Price: ¥Inquiry |
2023-09-13 |
Linifanib
Price: ¥Inquiry |
2020-12-08 |
Linifanib (ABT-869)
Price: ¥Inquiry |
Get all price from the following link:
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved